We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

50 hedge funds and large institutions have $58M invested in Concert Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 10

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

4% more funds holding

Funds holding: 48 → 50 (+2)

26% less capital invested

Capital invested by funds: $78.7M → $58M (-$20.7M)

Holders
50
Holders Change
+2
Holders Change %
+4.17%
% of All Funds
1.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
16
Reduced
10
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$3.85M
2
Principal Financial Group
Principal Financial Group
Iowa
+$1.21M
3
BG
BlackRock Group
United Kingdom
+$964K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$534K
5
Citigroup
Citigroup
New York
+$533K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$3.06M
2
BC
Broadfin Capital
New York
-$2.69M
3
BFA
BlackRock Fund Advisors
California
-$1.57M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.34M
5
Marshall Wace
Marshall Wace
United Kingdom
-$807K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$286K +$273K +28,310 New
Geode Capital Management
27
Geode Capital Management
Massachusetts
$211K -$31.8K -3,288 -14%
Millennium Management
28
Millennium Management
New York
$209K +$52.1K +5,396 +35%
Barclays
29
Barclays
United Kingdom
$205K +$140K +14,542 +244%
BFA
30
BlackRock Fund Advisors
California
$203K -$1.57M -162,494 -89%
COPPSERS
31
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$192K +$184K +19,018 New
TC
32
TFS Capital
Pennsylvania
$163K +$156K +16,177 New
SIM
33
Spark Investment Management
New York
$150K -$36.7K -3,800 -20%
LP
34
LMR Partners
United Kingdom
$146K +$139K +14,394 New
BPC
35
Banque Pictet & Cie
Switzerland
$137K +$19.6K +2,029 +18%
BCM
36
Bridgeway Capital Management
Texas
$136K +$130K +13,500 New
Wells Fargo
37
Wells Fargo
California
$131K +$86.1K +8,920 +221%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$122K +$117K +12,102 New
Morgan Stanley
39
Morgan Stanley
New York
$111K -$513K -53,125 -83%
PAM
40
Paradigm Asset Management
New York
$69.2K +$66.2K +6,850 New
TRCT
41
Tower Research Capital (TRC)
New York
$32K +$14.5K +1,503 +90%
Creative Planning
42
Creative Planning
Kansas
$30K +$29K +3,000 New
BJ
43
BlackRock Japan
Japan
$19K +$18.4K +1,910 New
OIA
44
Optimum Investment Advisors
Illinois
$15K +$14.5K +1,500 New
BIM
45
BlackRock Investment Management
Delaware
$11K -$154K -15,986 -94%
WA
46
Winfield Associates
Ohio
$10K – – –
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$3K – – –
Bank of Montreal
48
Bank of Montreal
Ontario, Canada
$2K +$1.54K +160 New
GC
49
Globeflex Capital
California
$1K +$1.25K +130 New
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$697 +$666 +69 New
1
2
3

CNCE Hedge Fund Activity: Q2 2014 in Review

50 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2014, worth a combined $58M — down 26% from $78.7M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CNCE positions and 13 closed out — a net gain of 2 holders — while 16 added to existing stakes and 10 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $3.85M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $3.06M sold.

  • 50 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2014, up from 48 in Q1 2014.
  • Funds reported $58M of Concert Pharmaceuticals, Inc. stock for Q2 2014, down 26% quarter-over-quarter.
  • 15 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2014 and 13 closed out, a net change of +2 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q2 2014 was Baker Bros. Advisors, an estimated $3.85M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q2 2014 was JP Morgan Chase, an estimated $3.06M sold.

Based on aggregated 13F filings for Q2 2014.